Skip to main content
Top
Published in: Tumor Biology 6/2010

01-12-2010 | Research Article

CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma

Authors: Isik Didem Karagoz, Mehmet Ozaslan, Beyhan Cengiz, Mehmet Emin Kalender, Ibrahim Halil Kilic, Serdar Oztuzcu, Bulent Gogebakan, Abdullah Tuncay Demiryurek

Published in: Tumor Biology | Issue 6/2010

Login to get access

Abstract

The family of cell division cycle 25 (CDC25) phosphatase is one of the important regulators of the cell cycle progression. In mammalian cells, three isoforms have been identified: CDC25A, CDC25B, and CDC25C. CDC25A is required to enter S time, and the overexpression of this phosphatase accelerates the entrance to S time. CDC25A overexpression could render tumor cells less sensitive to DNA replication checkpoints, thereby contributing to their genomic instability. We aimed to investigate, for the first time, the frequency of human CDC25A gene SNPs in metastatic and non-metastatic breast cancer. Total number of 281 eligible patients with histologically confirmed incident of breast cancer and 137 cancer-free controls were included. The detection of CDC25A gene polymorphisms was achieved with real-time polymerase chain reaction and restriction fragment length polymorphism techniques. We found that the 263C/T polymorphism was significantly associated with breast cancer and risk of metastasis. The -350C/T polymorphism in the promoter region of CDC25A gene was found to associate with neither breast cancer nor metastasis. The other promoter polymorphism -51C/G in the CDC25A gene associated with breast cancer but not associated with metastasis. These data suggest that 263C/T and -51C/G polymorphisms of CDC25A gene could be candidate markers for earlier diagnosis and targets for breast cancer therapy.
Literature
1.
go back to reference Gürtunç E: Meme Kanserli Hastalarda CYP19 Geni Kodon 39 Trp/Arg Polimorfizminin ve Genotip Dağılımının Araştırılması. Yüksek Lisans Tezi. Çukurova Üniv Sağlık Bilimleri Ens Tıbbi Biyoloji ABD 2007. Gürtunç E: Meme Kanserli Hastalarda CYP19 Geni Kodon 39 Trp/Arg Polimorfizminin ve Genotip Dağılımının Araştırılması. Yüksek Lisans Tezi. Çukurova Üniv Sağlık Bilimleri Ens Tıbbi Biyoloji ABD 2007.
2.
go back to reference Yıldız Y: Meme Kanserli Hastalarda TNF ile İlişkili Apoptoz Uyarıcı Ligand ve Bcl-2 ile İlişkili X-Protein Gen Polimorfizmlerinin Araştırılması. Yüksek Lisans Tezi. İstanbul Üniv Sağlık Bilimleri Ens Moleküler Tıp ABD 2008. Yıldız Y: Meme Kanserli Hastalarda TNF ile İlişkili Apoptoz Uyarıcı Ligand ve Bcl-2 ile İlişkili X-Protein Gen Polimorfizmlerinin Araştırılması. Yüksek Lisans Tezi. İstanbul Üniv Sağlık Bilimleri Ens Moleküler Tıp ABD 2008.
3.
go back to reference Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006;240:261–7.CrossRefPubMed Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006;240:261–7.CrossRefPubMed
4.
go back to reference Hossfeld DK, Sherman CD, Love RR, Bosch FX: Klinik Onkoloji. Uluslararası Kanserle Savaş Birliği 1992; 5th edition, p 25. Hossfeld DK, Sherman CD, Love RR, Bosch FX: Klinik Onkoloji. Uluslararası Kanserle Savaş Birliği 1992; 5th edition, p 25.
5.
go back to reference Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed
6.
go back to reference Cangi MG, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M, et al. Role of the CDC25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.CrossRefPubMed Cangi MG, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M, et al. Role of the CDC25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.CrossRefPubMed
7.
go back to reference Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994;13:1549–56.PubMed Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994;13:1549–56.PubMed
8.
go back to reference Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994;13:4302–10.PubMed Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994;13:4302–10.PubMed
9.
go back to reference Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed
10.
go back to reference Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human CDC25A inactivation in response to S time inhibition and its role in preventing premature mitosis. EMBO Rep. 2000;1:71–9.CrossRefPubMed Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human CDC25A inactivation in response to S time inhibition and its role in preventing premature mitosis. EMBO Rep. 2000;1:71–9.CrossRefPubMed
11.
go back to reference Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997;57:2366–8.PubMed Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997;57:2366–8.PubMed
12.
go back to reference Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, et al. CDC25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7.PubMed Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, et al. CDC25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7.PubMed
13.
go back to reference Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997;88:947–52.PubMed Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997;88:947–52.PubMed
14.
go back to reference Wu W, Fan Y, Kemp B, Walsh G, Mao L. Overexpression of CDC25A and CDC25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–5.PubMed Wu W, Fan Y, Kemp B, Walsh G, Mao L. Overexpression of CDC25A and CDC25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–5.PubMed
15.
go back to reference Moreira Jr G, Colleoni GWB, Cangi MG, Murphy M, Sherburne B, et al. Reciprocal CDC25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003;12(3):128–32. Moreira Jr G, Colleoni GWB, Cangi MG, Murphy M, Sherburne B, et al. Reciprocal CDC25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003;12(3):128–32.
16.
go back to reference Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, et al. Differential expression of CDC25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001;81:465–73.PubMed Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, et al. Differential expression of CDC25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001;81:465–73.PubMed
17.
go back to reference Ray D, Kiyokama H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008;68(5):1251–3.CrossRefPubMed Ray D, Kiyokama H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008;68(5):1251–3.CrossRefPubMed
18.
go back to reference Cangi MG, Piccinin S, Pecciarini L, Talarico A, Cin ED, Grassi S, et al. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int J Cancer. 2008;123:1466–71.CrossRefPubMed Cangi MG, Piccinin S, Pecciarini L, Talarico A, Cin ED, Grassi S, et al. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int J Cancer. 2008;123:1466–71.CrossRefPubMed
20.
go back to reference Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW. A bioinformatics-based strategy identifies c-Myc and CDC25A as candidates for the Apmt mammary tumour latency modifiers. Genome Res. 2002;12:969–75.CrossRefPubMed Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW. A bioinformatics-based strategy identifies c-Myc and CDC25A as candidates for the Apmt mammary tumour latency modifiers. Genome Res. 2002;12:969–75.CrossRefPubMed
21.
go back to reference Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of CDC25A and CDC25B phosphatase in breast carcinoma. Breast Cancer. 2004;11:295–300.CrossRefPubMed Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of CDC25A and CDC25B phosphatase in breast carcinoma. Breast Cancer. 2004;11:295–300.CrossRefPubMed
Metadata
Title
CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma
Authors
Isik Didem Karagoz
Mehmet Ozaslan
Beyhan Cengiz
Mehmet Emin Kalender
Ibrahim Halil Kilic
Serdar Oztuzcu
Bulent Gogebakan
Abdullah Tuncay Demiryurek
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0075-z

Other articles of this Issue 6/2010

Tumor Biology 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine